Main Article Content
Aim: Abuse of psychoactive substances among secondary school adolescents is a huge problem globally. This study examined the influence of psychoactive substance use on psychopathological symptoms among secondary school adolescents in Ede, Osun State, Southwestern Nigeria.
Study Design: Cross-sectional survey design.
Place of Study: Redeemer’s University Ede Osun state, Southwestern Nigeria.
Methodology: Four hundred and ninety-six (496) secondary school adolescents (mean age 15.7 years) were purposively selected from five secondary schools in Ede metropolis. Substance Abuse Inventory (SABI) and Awaritefe Psychological Index (API Form-X) were used for data collection. Descriptive and inferential statistics were used for data analysis. Four hypotheses were tested using a Regression Analysis, Pearson Product Moment Correlation and Independent Sample t-test and at 0.05% level of significance.
Results: A high prevalence of psychopathological symptoms was observed among the participants. Psychoactive substance use was observed to jointly and significantly predict psychopathological symptoms (R² = .106, p = .001). Sex has significant influence on manifested psychopathological symptoms with female adolescents reporting higher mean scores on insomnia, intellect disorder, heat disorder, mood disorder, alimentary track disorder and general psychopathology. Age was observed to be inversely correlated with psychopathological symptoms. Significant difference was found between drug users and non-user on severities of psychopathological symptoms.
Conclusions: This research finding indicates a high prevalence of psychopathological symptoms; that the use psychoactive substance is significantly linked the psychopathological symptoms and that age of involvement in psychoactive substance is also a significant risk factor for psychopathology among adolescents.
World Health Organization (WHO). Mental health: Strengthening our response. Substance Abuse; 2014.
Smith SR, Handler L. The clinical assessment of children and adolescents: a practitioner's handbook; 2007.
Manwell LB, Czabala JC, Ignaczak M, Mundt MP. Correlates of depression among heavy drinkers in Polish primary care clinics. International Journal of Psychiatry in Medicine. 2004;34:165-78.
National Institute on Drug Abuse (NIDA). Prescription and Over the Counter Medications; 2013.
NIDA. Common comorbidities with substance use disorder; 2018.
(Retrieved November 25 2019)
National Institute of Alcohol Abuse and Alcoholism Drug Abuse (NIAAA): Alcohol's Effects on the Body; 2000.
United Nations Office on Drugs and Crime (UNODC): UNDOC. World Drug Report 2010, United Nations Publication, Vienna, Austria; 2010.
United Nations Office on Drugs and Crime (UNODC). World Health Organization Expert Committee on dependence producing drugs. Fourteenth Report Urban Adolescent” Child Development. 2005;61: 2032–2046.
Omokhodion F, Faseru B. Perception of cigarette smoking and advertisement among senior secondary school students in Ibadan, Southwestern Nigeria. West African Journal of Medicine. 2007;26(3): 206–209.
Igwe WC, Ojinnaka N, Ejiofor SO, Emechebe GO, Ibe BC. Socio demographic correlates of psychoactive substance abuse among secondary School students in Enugu, Nigeria. Europe Journal of Social Science. 2009;12(2):277.
Oshodi OY, Aina OF, Onajole AT. Substance use among secondary school students in an urban setting in Nigeria: Prevalence and associated factors. African Journal Psychiatry (Johannesbg). 2010;13 (1):52–57.
Oliha JA. Adolescent and drug abuse in tertiary institution implication for counseling. British Journal of Education: European Centre for Research Training and Development UK. 2014;2(1):1-9,
National Institute of Drug Abuse (NIDA). Health consequences of dug misuse; 2017.
Ross S, Peselow E. Co-occurring psychotic and addictive disorders: neurobiology and diagnosis. Clin Neuropharmacol. 2012;35(5):235-243.
Fontenelle LF, Oostermeijer S, Harrison BJ, Pantelis C, Yücel M. Obsessive-compulsive disorder, impulse control disorders and drug addiction: Common features and potential treatments. Drugs. 2011;71(7):827-840.
Aubin HJ, Rollema H, Svensson TH, Winterer G. Smoking, quitting and psychiatric disease: A review. Neurosci Biobehav Rev. 2012;36(1):271-284.
Minichino A, Bersani FS, Calò WK, et al. Smoking behaviour and mental health disorders-mutual influences and implications for therapy. Int J Environ Res Public Health. 2013;10(10):4790-4811.
Center for Behavioral Health Statistics and Quality. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017.
Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health. 2013; 28:388-406.
Brady KT, Haynes LF, Hartwell KJ, Killeen TK. Substance use disorders and anxiety: A treatment challenge for social workers. Soc Work Public Health. 2013;28(3-4):407-423.
Wolitzky-Taylor K, Operskalski JT, Ries R, Craske MG, Roy-Byrne P. Understanding and treating comorbid anxiety disorders in substance users: Review and future directions. J Addict Med. 2011;5(4):233-247.
Magidson JF, Liu SM, Lejuez CW, Blanco C. Comparison of the course of substance use disorders among individuals with and without generalized anxiety disorder in a nationally representative sample. J Psychiatr Res. 2012;46(5):659-666.
Torrens M, Gilchrist G, Domingo-Salvany A. psyCoBarcelona Group. Psychiatric comorbidity in illicit drug users: Substance-induced versus independent disorders. Drug Alcohol Depend. 2011;113(2-3):147-156.
Flórez-Salamanca L, Secades-Villa R, Budney AJ, García-Rodríguez O, Wang S, Blanco C. Probability and predictors of cannabis use disorders relapse: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2013; 132:127-133.
Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014;71(3):248-254.
Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability and comorbidity of DSM-IV drug abuse and dependence in the United States: Results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64(5):566-576.
Pennay A, Cameron J, Reichert T, et al. A systematic review of interventions for co-occurring substance use disorder and borderline personality disorder. J Subst Abuse Treat. 2011;41(4):363-373.
Pettinati HM, O’Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: A new therapeutic target. Am J Psychiatry. 2013; 170(1):23-30.
De Alwis D, Lynskey MT, Reiersen AM, Agrawal A. Attention-deficit/hyperactivity disorder subtypes and substance use and use disorders in NESARC. Addict Behav. 2014;39(8):1278-1285.
Harstad E, Levy S, Abuse C on S. Attention-deficit/hyperactivity disorder and substance abuse. Pediatrics. 2014;134(1): e293-e301.
Swadi H. Substance misuse in adolescents. Advances in Psychiatric Treatment. 2000;6:201–210.
Gilvary E. Substance use and misuse by children and adolescents. Curr Opinion Psychiatry. 1999;12:409–413.
Omoluabi PF. A review of the incidence of nonprescription psychoactive substance use/misuse in Nigeria. Int J of the Addictions. 1995;30(4):445-458.
Awaritefe AA. The Awaritefe psychological index. Nigerian Journal of Clinical Psychology. 1982;1(2):42-51.
Akinnawo E, Ofovwe CA validation study of API-Form X on Nigerian Adolescents. IFE PsychologyIA. 2012;20(2):41.
WHO. Integrating mental health into primary care: A global perspective. Geneva; 2008.
Owoyemi E. Medical experts say 64 million Nigerians suffer from mental illness. Premium Times; 2013.
Akpunne BC. Prevalence and nature of child neglect and mental health status of secondary school adolescents. Advances in Social Science Research Journal. 2015; 2(4):233-247.
Akpunne BC, Akinnawo EO. Domestic violence influence on psychological distress among institutionalized adolescents. International Journal of Research in Economics and Social Sciences. 2017;7(8):28-44.
Patel V, Fisher AJ, Hetrick S. McGorry P. Mental health of young people: A global public-health challenge. Lancet. 2007;369: 1302–13.
Storrie K, Ahern K, Tuckett AA. Systematic review: Students with mental health problems-a growing problem. International Journal of Nursing Practice. 2010;16(1):1-6.
Kessler RC, Avenevoli SR, Merikangas K. Mood disorders in children and adolescents: An epidemiologic perspective. Biol Psychiatry. 2005;49: 1002-14.
Merikangas KR. He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: Results from the National Comorbidity Survey Replication--Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49 (10):980-9.
National Institute of Mental Health (NIMH). Anxiety Disorders; 2016.
Baigent M. Managing patients with dual diagnosis in psychiatric practice. Curr Opin Psychiatry. 2012;25(3):201-205.
Goldstein BI, Bukstein OG. Comorbid substance use disorders among youth with bipolar disorder: Opportunities for early identification and prevention. J Clin Psychiatry. 2010;71(3):348-358.
Santucci K. Psychiatric disease and drug abuse. Curr Opin Pediatr. 2012;24(2):233-237.
Legg TJ. Recognizing forms of self-medication. Healthline; 2019.
(Retrieved September 28th 2019)
Hyman S. Mental disorders. In: Disease control priorities related to mental, neurological, developmental and substance abuse disorders, 2nd ed. Geneva, World Health Organization: 2006; 1–20.
Light M, Grant E, Hopkins K. Gender differences in substance misuse and mental health amongst prisoners. Results from the Surveying Prisoner Crime Reduction (SPCR) longitudinal cohort study of prisoners. Ministry of Justice Analytical Services; 2013.
Hagen EH, Rosenström T. Explaining the sex difference in depression with a unified bargaining model of anger and depression: Evil Med Public Health. 2016; 1:117-32.
Ritchie H, Roser M. Mental Health; 2019.
Institute of Health Metrics and Evaluation (IHME), Global Burden of Disease (GBD); 2017.
National Institute of Drug Abuse (NIDA). Relationship between Drug Abuse and Anxiety Disorder; 2015.